Literature DB >> 10410750

Hallucinations in Parkinson's disease: the clinical syndrome.

C G Goetz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10410750

Source DB:  PubMed          Journal:  Adv Neurol        ISSN： 0091-3952


× No keyword cloud information.
  8 in total

Review 1.  Neuropsychiatric non-motor aspects of Parkinson's disease.

Authors:  B R Thanvi; S K Munshi; N Vijaykumar; T C N Lo
Journal:  Postgrad Med J       Date:  2003-10       Impact factor: 2.401

Review 2.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

3.  Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.

Authors:  Günes Kiziltan; Sibel Ozekmekçi; Sibel Ertan; Turan Ertan; Ethem Erginöz
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

4.  Peduncular hallucinosis: a syndrome of impaired reality monitoring.

Authors:  Thomas Benke
Journal:  J Neurol       Date:  2006-09-27       Impact factor: 4.849

Review 5.  Hallucinations in Parkinson disease.

Authors:  Nico J Diederich; Gilles Fénelon; Glenn Stebbins; Christopher G Goetz
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

6.  Psychosis in Parkinson's Disease.

Authors:  Laura Marsh
Journal:  Curr Treat Options Neurol       Date:  2004-05       Impact factor: 3.598

Review 7.  Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.

Authors:  Caroline H Williams-Gray; Thomas Foltynie; Simon J G Lewis; Roger A Barker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

8.  Delirium and high fever are associated with subacute motor deterioration in Parkinson disease: a nested case-control study.

Authors:  Atsushi Umemura; Tomoko Oeda; Satoshi Tomita; Ryutaro Hayashi; Masayuki Kohsaka; Kwiyoung Park; Hiroshi Sugiyama; Hideyuki Sawada
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.